key: cord-0278926-lip1r1kc
authors: Shafiee, Arman; Teymouri Athar, Mohammad Mobin; Nassar, Mahmoud; Seighali, Niloofar; Aminzade, Dlnya; Fattahi, Payam; Rahmannia, Maryam; Ahmadi, Zahra
title: Comparison of COVID-19 outcomes in patients with Type 1 and Type 2 diabetes: A systematic review and meta-analysis
date: 2022-05-27
journal: nan
DOI: 10.1016/j.dsx.2022.102512
sha: 628f895877470fd7682333f3e0cfae65982f3078
doc_id: 278926
cord_uid: lip1r1kc

Background and aims This systematic review and meta-analysis aimed to evaluate the current evidence available to investigate clinical outcomes between patients with type 1 and type 2 diabetes. Methods MEDLINE (Pubmed), Scopus, Web of Science, Cochrane library, Google scholar and Clinicaltrials.gov were searched. Randomized controlled trials (RCTs), non-randomized trials, and observational studies were eligible for inclusion. National Institutes of Health Quality Assessment Tool was used to assess the quality. Data were pooled by the Restricted-maximum-likelihood random-effects approach. Results Total 11 studies comprising 7690415 individuals included in this study. The log OR for the pooled data for all-cause mortality rate was −0.71 (95% CI: −1.38 to −0.03). Based on the pooled results, type 1 diabetic COVID-19 patients may have a better prognosis for mortality. There were no significant differences between groups in term of ICU-admission log OR -0.22 (95% CI: −0.81 to 0.37), and hospitaliztion log OR -0.48 (95% CI: −1.23 to 0.27). Based on our descriptives analyses after adjusting for age and comorbidities, the high-risk group in three studies was type 2 diabetes, and in five studies was type 1. Two studies reported no significant difference between these groups in relevant outcomes. Conclusion There were no significant differences in disease severity between type 1 and type 2 diabetes. Based on the unadjusted data available, the mortality rate for people with type 1 diabetes was shown to be lower than that for people with type 2. As data on these subjects is scarce, and the results obtained from studies are heterogeneous, further research with adequate sample sizes is needed to precisely compare the outcomes of COVID-19 between type 1 and type 2 diabetes.

World Health Organization (WHO) declared novel Coronavirus Disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) a pandemic for March 11, 2020 (1) . As a result, its high transmissibility has caused more than 6 million deaths worldwide, and the number continues to increase as new strains emerge (2) . Symptoms of the disease may range from asymptomatic or mild to severe pneumonia, multi-organ failure, acute respiratory distress syndrome (ARDS), and even death (3, 4) . Comorbidities are one of many risk factors contributing to the severity of the disease (5) . Studies have established a significant relationship between the risk of mortality in COVID-19 patients and certain comorbidities, including chronic kidney disease (CKD), chronic lung disease, diabetes mellitus (DM), hypertension, aging, immunosuppression, and obesity (6) . An analysis by the Chinese CDC of 72314 patients indicates that diabetes is the second most common cause of death (7,3%) after heart disease (10,5%), which equates to a rate of 2,3% in the general population (7) .

Diabetes mellitus (DM) is a chronic disease characterized by glucose dysregulation and severe long-term complications affecting multiple organs. Type 1 diabetes (T1D) and type 2 diabetes (T2D) are the most prevalent subtypes of diabetes. Nearly half a billion people suffer from DM, making it one of the most important risks for severe COVID-19. Moreover, DM is often associated with other risk factors, including hypertension, nephropathy, obesity, cardiovascular disease (CVD), a proinflammatory and hypercoagulable state that makes the individual more susceptible to hyperglycemia more severe forms of COVID-19 (8) (9) (10) (11) . The prevalence of T1D ranged from 0.15% to 28.98% among COVID-19 patients (12) . The risk of progression to severe and death is more significant in patients with diabetes mellitus (DM) (13) . As a result of the impairment of the immune system caused by DM, an uncontrolled immune response was produced against SARS-CoV-2 (14) . Bidirectional interrelationships between SARS-CoV-2 and DM complications will result in a more complex situation in terms of disease severity.

Due to the high prevalence of diabetes among COVID-19 patients and the special care that is needed during infection, we are concerned about preventing and treating COVID-19 in patients with diabetes. A number of studies have reported an association between diabetes and a higher risk of severe COVID-19; however, it is unclear which types of diabetes are associated with a J o u r n a l P r e -p r o o f higher risk of severe disease progression. In order to fill this evidence gap, we conducted a systematic review and meta-analysis to compare T1D and T2D in terms of disease severity.

We conducted a systematic review and meta-analysis in accordance with the recommendations of the Cochrane Handbook (15) . We used the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) in this study (16) . Our study protocol is registered at PROSPERO under the number CRD42022319173.

Pubmed/MEDLINE, Scopus, Web of Science, Cochrane library, and Clinicaltrials.gov were assessed by our reviewers (N.S and D.A and M.R and Z.A) who designed a search strategy using the search string: ("COVID-19"[Mesh]) OR ("SARS-CoV-2"[Mesh]) OR "COVID-19" OR "Coronavirus" OR "nCoV" OR "SARS-Cov-2" AND ("Diabetes "[Mesh]) OR "Diabetes" OR "diabetes mellitus" OR "diabetes mellitus type 1" OR "diabetes mellitus type 2" OR "diabetes type 1" OR "diabetes type 2". All publications were retrieved up to February 16, 2022. Additionally, we searched the reference sections of other studies for relevant publications. The result was exported to the EndNote X9 program for further screening.

Studies recognized as eligible for inclusion included: 1) confirmed COVID-19 patients; 2) patients diagnosed with T1D and T2D; 3) studies evaluating outcomes relevant to this topic; and 4) studies reporting both T1D and T2D infected with SARS-CoV-2. We included randomized controlled trials (RCTs), non-randomized trials, and observational studies. We excluded case reports, case series, non-English articles, and studies that involved patients <18 years old and pregnant women. Additionally, studies that focused on only one type of diabetes (for instance, studies focused exclusively on T2D) were excluded. Two reviewers independently reviewed the titles and abstracts (N.S and D.A), then the full texts in EndNote. All disagreements were resolved via discussion with a third reviewer to reach an agreement (AS). Data were extracted from text, tables, figures, graphs, and supplementary materials into an excel spreadsheet. Two reviewers (N.S. and A.S.) independently extracted author/year, country, study type, population, duration, number of patients in each trial, as well as outcome data.

J o u r n a l P r e -p r o o f Two reviewers (M.T and A.S) independently evaluated the included studies using the NIH risk of bias checklist (17) . The checklist included 14 questions designed to assess the quality of observational cohort and cross-sectional studies. The studies with 10 or more yeses are rated as "Good", 7-9 yeses as "Fair", and fewer than 7 yeses are rated as "Poor".

The meta-analysis outcomes were all cause mortality, hospitalization, and ICU admission rates for COVID-19 patients with T1D compared to COVID-19 patients with T2D.

In this study, data were pooled by the Restricted-maximum-likelihood random-effects approach since the indicators were designed to vary across studies, and there was some variation between the studies. A log odds ratio (log OR) was calculated to summarize the overall effects of outcomes.

A p-value of < 0.05 was considered significant for the effect estimate. The I 2 statistic was used to assess study heterogeneity, with I2 values of <50%, 50% to 75%, and >75%, respectively, indicating low, moderate, and high levels of heterogeneity. Although I 2 is the most commonly used measure of heterogeneity, the I 2 value increases as the number of trials increases. This makes it challenging to compare I 2 across analyses. Therefore, we report both I 2 and Tau for each analysis.

Publication bias was assessed using funnel plots inspection and Egger's regression test for funnel plot asymmetry. To evaluate the effect of individual studies on the pooled results, we conducted a leave-one-out sensitivity analysis. A sub-group analysis was conducted for both the adjusted and unadjusted data. We used Stata version 16 statistical software (Stata Corp, College Station, TX, USA) for the quantitative synthesis.

A total of 2419 initial studies were identified, and 638 duplicates were removed ( Figure 1 ). After screening the titles and abstracts, 39 full-text articles were reviewed, and 11 studies were included.

Most of the studies were conducted in European countries, including Austria (n = 1), Sweden (n = 1), Scotland (n=1), France (n = 1), England (n = 4), and Turkey (n = 1). Two studies were conducted in the United States (n=2). The studies considered were all observational, and eight of them had a sample size of more than 1000 patients. Detailed characteristics of each study is provided in Table 1 . On the basis of the NIH checklist, the quality of included studies was J o u r n a l P r e -p r o o f evaluated as Good/Fair and none was rated Poor. Most of the studies did not provide additional information about blinding outcome assessors to the participants' exposure status or assessing the exposure in more than one study. 

There have been six studies reporting rates of hospitalization for T1D or T2D, including (19, 22-24, 28, 29) . We calculated the pooled log OR to be -0.48 (95% CI: -1.23 to 0.27) with high heterogeneity (I 2 = 97%, Tau= 0.78) between the groups. It 

The majority of the studies included in our quantitative synthesis that provided the necessary information for our synthesis were data from registries without any adjustment for age or other comorbidities between T1D and T2D patients with COVID-19 disease. In their own studies, however, they have reported their results after further adjustment as well as their unadjusted results. As a result of adjusting for age and comorbidities, the high-risk group in three studies was T2D, five studies were T1D, and two studies reported no significant difference between these groups in relevant outcomes.

To the best of our knowledge, this is the first systematic review and meta-analysis comparing the severity of COVID-19 between patients with T1D and T2D. This review included 11 studies with a total of 77583747 patients with concurrent SARS-CoV-2 infection and diabetes. This study examined the clinical outcomes of patients with diabetes to determine if there were any differences between the two groups of patients. Our clinical outcomes representing the severity of the disease included hospitalization, ICU admission, and mortality. As a result of our analyses, patients with T1D had a better outcome, although the difference was not statistically significant when comparing ICU admission and hospitalization rates. Furthermore, it should be noted that most of these results were obtained from unadjusted data collected from included studies, which did not take into consideration age and other comorbid conditions in these patients. Our descriptive synthesis considering the impact of other factors revealed an interesting result. Based on the majority of included studies, T1D patients were at a higher risk for COVID-19 after adjusting for age and other comorbidities.

Various reports from around the world indicate that the prevalence of diabetes among hospitalized COVID-19 patients can reach as high as 20% (30) . Further, epidemiological studies suggest that diabetes is more prevalent among individuals with severe disease and is associated with a higher mortality rate (31) . Furthermore, patients with diabetes are more likely to acquire infections such as lower respiratory tract infections due to impaired immune function, including a lack of proper phagocytosis by neutrophils, macrophages, and monocytes (32) . Hyperglycemia is also associated with an increased risk of severe infections (33) . Therefore, patients with diabetes are J o u r n a l P r e -p r o o f at greater risk of developing more severe forms of the disease and even death. Together, these factors result in higher COVID-19 morbidity and mortality, placing a great burden on healthcare systems and other aspects of people's lives. Considering public health perspectives, with the emergence of new variants and their rapid spread, the number of patients admitted to hospitals, especially intensive care units, has grown dramatically. As such, it is crucial to establish protocols that prioritize patients based on their estimated risk of severe disease and death. Special attention should be paid to patients with conditions associated with more severe outcomes, such as older age, diabetes, hypertension and obesity, as they are more likely to suffer complications. As a result of this condition, COVID-19 can be prevented through improved social distancing and personal protective equipment, enhanced patient vigilance, and a lower threshold for testing, hospitalization, and intensive care for patients with diabetes.

Both T1D and T2D are the most prevalent types of diabetes mellitus. Although both groups are at risk of severe outcomes, there are differences between them as two pathophysiologically distinct conditions. In COVID-19 patients with both types of diabetes, the mortality rate is associated with age, male gender, cardiovascular disease (CVD), renal impairment, obesity, and underweight (34). BMI could be a determining factor when comparing these two subtypes since it is more prevalent among patients with T2D. According to Trieu et al., elevated BMI is evident among patients with T2D when these two subtypes are compared (35) . During the pandemic, various factors, including lockdown, sedentary lifestyle, decreased physical activity, and increased calorie intake contributed to increased population body mass index. According to the CDC, the BMI increased twofold during the pandemic compared to the period before the pandemic (35).

As Rawshani et al. reported, there is an independent association between T2D and risk of hospitalization, admission to ICU, and mortality (34). They noted that the risk remains, but it was reduced after adjusting for confounding factors (cite). Despite adjusting for confounding factors, there was no independent risk of these outcomes in T1D patients. Ultimately, the researchers concluded that long-term complications of the disease influenced the risk in patients with T1D. In addition, the researchers found that women had a lower risk for these outcomes among patients with T2D, whereas the risk was the same for patients with T1D (34).

According to the English national audit cohort, compared to individuals without diabetes, the odds ratios for COVID-19 deaths in the hospital were 3.51 in T1D patients and 2.03 in T2D patients (28) . Due to limitations associated with the datasets used in the study, confounding factors such as hypertension, CKD, BMI, and smoking status were not adjusted (25) . A matched case-control J o u r n a l P r e -p r o o f study from Scotland reported ORs of 2.75 and 1.60 for T1D and T2D, respectively (27) . Lasbleiz et al. reported a much higher hospitalization risk for T2D patients after adjusting for age and BMI, whereas T1D patients may be reassured (28) .

In Gregory et al. 's study, the odds of hospitalization and more severe disease were similar between T1D patients and T2D patients (22) . According to Demirci et al., a nationwide cohort study was conducted with 149,671 patients who tested positive for COVID-19 (26) . They found that despite adjusting for age, gender, and microvascular and macrovascular complications, patients with T1D had a threefold greater risk of ICU admission and mortality than people with T2D. They described the scarcity of data regarding T1D due to the low prevalence of T1DM, the younger age of T1DM patients compared to T2DM patients, and the fact that elders are at a greater risk of becoming affected by COVID-19. They concluded that these two subtypes of diabetes mellitus are entirely different in their clinical outcomes based on their findings. In addition, the different immune dysfunction and pathophysiology may be contributing to the higher mortality rate associated with T1D (26) . COVID-19 mortality has an inverse relationship with eGFR (30) . As eGFR values may change after taking anti-diabetic medications, there is concern that the use of these drugs may impact mortality rates.

Our study has several strengths. This is the first systematic review and meta-analysis to examine COVID-19 severity differences between T1D and T2D. We conducted a comprehensive database search in order to obtain the most comprehensive results and accurate conclusions. The analysis of each outcome was also based on at least five studies. Additionally, most of the studies included measured and differentiated the level of baseline characteristics that may vary in amount or level, such as HbA1c. These findings may have implications for clinical practice and public health policies. While chronic hyperglycemia is the primary cause of diabetes mellitus, type 1 and type 2 diabetes differ in terms of their pathophysiology, preventive methods, age of onset, management, and epidemiological characteristics. As a result, the approaches needed to treat these two types of diabetes differ. It is beneficial for us to identify which type of diabetes leads to more severe forms of COVID-19 in order to determine the preventive measures needed to reduce the number of affected individuals and further complications associated with concurrent COVID-19 infection. Specifically tailored education and management can be provided to patients with each type of diabetes to achieve this objective.

The fact that T2D is more prevalent and develops at an older age than T1D indicates that the disease severity in patients with these two types of diabetes warrants special consideration for prevention and management. Furthermore, management of T1D is based on insulin therapy. On the other hand, the management of T2D includes a variety of anti-diabetic medications, which may cause different side effects, increasing the risk of alterations to the health status of patients. Diabetic ketoacidosis (DKA) is a severe acute metabolic condition characterized by acidosis, ketosis, and hyperglycemia that occurs more frequently among patients with type 1 diabetes (36) .. It is important to assess the risk of severe disease for patients who are more vulnerable to DKA as this is a lifethreatening condition. We found that both types of patients have the same risk of developing severe disease; therefore, there is no need to prioritize these two patient types when it comes to providing health care services.

As our study was subject to several limitations, its results should be interpreted with caution. Most of the analyzed studies were cohort studies, so they may be prone to bias related to their retrospective nature. The populations of the included studies were clinically heterogeneous. For example, one study included pediatric patients, while others included adult patients. In addition, some studies included very few participants, whereas others were national studies including large numbers of participants. The timing of the studies and the region in which they were conducted may have affected the results, as there were a number of differences between included studies. Furthermore, the heterogeneity of the results obtained from the studies is high; however, metaanalyses based on observational studies are often highly heterogeneous (37) . Lastly, it should be noted that most of our quantitative synthesis includes unadjusted data for age, gender, and other comorbidities due to the fact that confounding factors such as elderly age, cardiovascular disease, hypertension, and obesity are associated with severe COVID-19 and increased mortality.

We conclude, based on our results, that there are no significant differences between T1D and T2D in terms of severity of the disease. The mortality rate for people with T1D was observed to be lower than that for people with T2D based on the unadjusted data available. As data on these subjects is scarce, and the results obtained from studies are heterogeneous, further research with adequate sample sizes is needed to precisely compare the outcomes of COVID-19 between T1D and T2D. 

No Conflict of interest.

The authors declare no funding information.

Not applicable.

Not applicable.

Data sharing is available by contacting corresponding author. in patients with type 1 and type 2 Diabetes . A) The rate of mortality was significantly lower in patients with type 1 diabetes, B) No significant difference was observed in terms of ICU admission between type 1 and type 2 diabetes, C) No significant difference was observed in terms of hospitalization between type 1 and type 2 diabetes, . 

A Comprehensive Literature Review on the Clinical Presentation, and Management of the Pandemic Coronavirus Disease 2019 (COVID-19)

Lack of type 1 diabetes involvement in SARS-COV-2 population: Only a particular coincidence

Full spectrum of COVID-19 severity still being depicted -Authors' reply

Current systematic reviews and meta-analyses of COVID-19

Comorbidity and its Impact on Patients with COVID-19

Antibody response following SARS-CoV-2 vaccination among patients with type 2 diabetes mellitus: A systematic review

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention

COVID-19 and Diabetes: Understanding the Interrelationship and Risks for a Severe Course

Global trends in diabetes complications: a review of current evidence

Chronic comorbidities in children with type 1 diabetes: a population-based cohort study

The potential use of urinary transferrin, urinary adiponectin, urinary Retinol Binding Protein, and serum zinc alpha 2 glycoprotein levels as novel biomarkers for early diagnosis of diabetic nephropathy: A casecontrol study

The association between COVID-19 and type 1 diabetes mellitus: A systematic review

Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: a metaanalysis

Is diabetes mellitus a wrongdoer to COVID-19 severity?

Cochrane handbook for systematic reviews of interventions

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: what are they and which is better

COVID-19 fatality prediction in people with diabetes and prediabetes using a simple score upon hospital admission

Severe COVID-19 in people with type 1 and type 2 diabetes in Sweden: A nationwide retrospective cohort study

Effect of COVID-19 on the clinical course of diabetic ketoacidosis (DKA) in people with type 1 and type 2 diabetes

Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study

Severity Is Tripled in the Diabetes Community: A Prospective Analysis of the Pandemic's Impact in Type 1 and Type 2 Diabetes

Associations between body-mass index and COVID-19 severity in 6.9 million people in England: a prospective, community-based, cohort study

Higher rate of COVID-19 mortality in patients with type 1 than type 2 diabetes: a nationwide study

Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study

Higher rate of COVID-19 mortality in patients with type 1 than type 2 diabetes: a nationwide study

Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland

Phenotypic Characteristics and Development of a Hospitalization Prediction Risk Score for Outpatients with Diabetes and COVID-19: The DIABCOVID Study

Underlying Medical Conditions Associated With Severe COVID-19 Illness Among Children

COVID-19 fatality prediction in people with diabetes and prediabetes using a simple score upon hospital admission

Clinical Characteristics and Risk Factors for Mortality of COVID-19 Patients With Diabetes in Wuhan, China: A Two-Center

Infections in patients with diabetes mellitus

Diabetes and the risk of hospitalisation for infection: the Atherosclerosis Risk in Communities (ARIC) study

Severe COVID-19 in people with type 1 and type 2 diabetes in Sweden: A nationwide retrospective cohort study

SARS-CoV-2 infection in hospitalized children with type 1 and type 2 diabetes

The Evolution of Diabetic Ketoacidosis: An Update of its Etiology, Pathogenesis and management

Challenges in meta-analyses with observational studies

J o u r n a l P r e -p r o o f Rawsha ni, (19